Literature DB >> 28638738

Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

Elizabeth L McMichael1, Nicholas B Courtney2, Megan C Duggan1, Robert Wesolowski3, Dionisia Quiroga3, Sri Vidya Kondadasula2, Lakhvir S Atwal2, Neela Bhave2, Eric Luedke4, Alena Cristina Jaime-Ramirez5, Amanda R Campbell1,6, Xiaokui Mo7, John C Byrd8, William E Carson Iii4,9,1.   

Abstract

Natural killer (NK) cells are innate immune effector cells that play a crucial role in immune surveillance and the destruction of cancer cells. NK cells express a low-affinity receptor for the Fc or constant region of immunoglobulin G (FcγRIIIa) and multiple cytokine receptors that respond to antibody-coated targets and cytokines in the tumor microenvironment. In the present work, microarray gene expression analysis revealed that the IL-21 receptor (IL-21R) was strongly upregulated following FcR stimulation. The IL-21R was found to be upregulated on FcR-stimulated NK cells at the transcript level as determined by reverse transcription polymerase chain reaction (RT-PCR). Immunoblot analysis revealed that protein expression of the IL-21R peaked at 8 h post-stimulation of the FcR. Inhibition of the mitogen-activated protein kinase (MAPK) pathway downstream of the FcR blocked the induction of IL-21R expression. Increased expression of the IL-21R sensitized NK cells to IL-21 stimulation, as treatment of FcR-stimulated NK cells led to significantly increased phosphorylation of STAT1 and STAT3, as measured by intracellular flow cytometry and immunoblot analysis. Following FcR-stimulation, IL-21-activated NK cells were better able to mediate the lysis of trastuzumab-coated human epidermal growth factor receptor 2 (HER2+) SK-BR-3 tumor cells as compared to control-treated cells. Likewise, IL-21-induced NK cell secretion of IFNγ following exposure to antibody-coated tumor cells was enhanced following FcR-stimulation. The analysis of NK cells from patients receiving trastuzumab therapy for HER2+ cancer exhibited increased levels of the IL-21R following the administration of antibody suggesting that the presence of monoclonal antibody-coated tumor cells in vivo can stimulate the increased expression of IL-21R on NK cells.

Entities:  

Keywords:  Fc receptor; FcgammaRIIIa; IL-21; IL-21 receptor; natural killer cell

Year:  2017        PMID: 28638738      PMCID: PMC5467998          DOI: 10.1080/2162402X.2017.1312045

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  51 in total

1.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Authors:  T A Fehniger; M H Shah; M J Turner; J B VanDeusen; S P Whitman; M A Cooper; K Suzuki; M Wechser; F Goodsaid; M A Caligiuri
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

2.  Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS.

Authors:  Nia D Banks; Nicole Kinsey; Janice Clements; James E K Hildreth
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

3.  Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.

Authors:  Henrik Søndergaard; Elisabeth D Galsgaard; Monica Bartholomaeussen; Per Thor Straten; Niels Odum; Kresten Skak
Journal:  J Immunother       Date:  2010-04       Impact factor: 4.456

4.  IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

Authors:  Rachel Ettinger; Gary P Sims; Anna-Marie Fairhurst; Rachel Robbins; Yong Sing da Silva; Rosanne Spolski; Warren J Leonard; Peter E Lipsky
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

5.  An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.

Authors:  Ian D Davis; Birte K Skrumsager; Jonathan Cebon; Theo Nicholaou; John W Barlow; Niels Peter Hundahl Moller; Kresten Skak; Dorthe Lundsgaard; Klaus Stensgaard Frederiksen; Peter Thygesen; Grant A McArthur
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

6.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

7.  IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.

Authors:  Emma Di Carlo; Alberto Comes; Anna Maria Orengo; Ombretta Rosso; Raffaella Meazza; Piero Musiani; Mario P Colombo; Silvano Ferrini
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

8.  In vivo antitumor activity of interleukin 21 mediated by natural killer cells.

Authors:  Gang Wang; Mary Tschoi; Rosanne Spolski; Yanyan Lou; Katsutoshi Ozaki; Chiguang Feng; Grace Kim; Warren J Leonard; Patrick Hwu
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

9.  Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.

Authors:  Cecile M Krejsa; Rick D Holly; Mark Heipel; Ken M Bannink; Rebecca Johnson; Richard Roque; Jane Heffernan; Julie Hill; Lay Chin; Felecia Wagener; Faith Shiota; Katherine Henderson; Pallavur V Sivakumar; Hong-Ping Ren; Fariba Barahmand-Pour; Don Foster; Chris Clegg; Wayne Kindsvogel; Rafael Ponce; Steven D Hughes; Kim Waggie
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.

Authors:  Mark J Smyth; Morgan E Wallace; Stephen L Nutt; Hideo Yagita; Dale I Godfrey; Yoshihiro Hayakawa
Journal:  J Exp Med       Date:  2005-06-20       Impact factor: 14.307

View more
  2 in total

1.  An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.

Authors:  Ashley Pinette; Elizabeth McMichael; Nicholas B Courtney; Megan Duggan; Brooke N Benner; Fouad Choueiry; Lianbo Yu; David Abood; Thomas A Mace; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2019-07-23       Impact factor: 6.968

Review 2.  CD47 as a promising therapeutic target in oncology.

Authors:  Hai Zhao; Shuangshuang Song; Junwei Ma; Zhiyong Yan; Hongwei Xie; Ying Feng; Shusheng Che
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.